Mr. Dirk Heitepriem of Aurora Europe reports

AURORA CANNABIS COMMENDS GERMANY'S LANDMARK LEGALIZATION ACHIEVEMENT

Aurora Cannabis Inc. is applauding the German government's final endorsement of cannabis legalization, marking a significant step forward in bolstering patient access to medical cannabis with the official passing of the Cannabis Act.

This change presents long overdue reform in favour of a more accessible medical cannabis market and commitment to patients. This reform follows the progressive change in leading countries like Canada and will serve as a benchmark for global expansion.

"Germany's reform brings significant advancements in patient access to medical cannabis and a much-needed liberal approach to cannabis that we have advocated in favour of," emphasized Dirk Heitepriem, vice-president, external affairs, Aurora Europe GmbH. "As a market leader, Aurora has been a steadfast supporter of patients. With cannabis descheduling, more patients gain access to treatment, reinforcing our dedication to patient outreach and comprehensive access to quality medical cannabis. Today's improved access underscores our commitment to see progressive change."

Alongside the cultural significance of Germany's advancements in cannabis legalization, these developments offer a distinct opening for Aurora, a leading provider of medical cannabis in Germany, to enhance its established footprint in the country.

The reclassification of cannabis as a non-narcotic is poised to inspire more patients to actively consult with their physician regarding medical cannabis, facilitating greater access, education and awareness for medical cannabis. Aurora once again congratulates the German government on the successful passing of cannabis law reforms that provide for improved patient care.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alta., Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co. as well as international brands Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched.

About Aurora Europe GmbH

Aurora Europe, headquartered in Berlin, Germany, is a subsidiary of Aurora Cannabis Inc., a global leader in the cannabis industry serving both medical and consumer markets, and dedicated to helping people improve their lives. Aurora Europe supplies high-quality medical cannabis products to patients throughout Europe. Aurora is one of the largest authorized importers and distributors of medical cannabis in the European Union and the United Kingdom. Aurora Deutschland, part of Aurora Europe GmbH, is one of three companies licensed to grow medicinal cannabis in Germany. Since May, 2022, Aurora Produktions GmbH has been producing one ton of medicinal cannabis annually in Leuna, Saxony-Anhalt. Aurora's internal network of EU GMP (good manufacturing practices) facilities delivers high-quality, premium medical cannabis to patients worldwide.

We seek Safe Harbor.